VTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN

Group 1 - The Rosen Law Firm is reminding purchasers of Vistagen Therapeutics, Inc. common stock between April 1, 2024, and December 16, 2025, of the March 16, 2026, lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Vistagen common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court by March 16, 2026, to serve as lead plaintiff [3] Group 2 - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is in development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6] - Defendants made positive assertions about fasedienol's future trial success based on prior positive results from the PALISADE-2 clinical trial, which allegedly misled investors [5] - The lawsuit claims that when the true details about the trial were revealed, investors suffered damages [6] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]